Lupin has reported results for second quarter ended September 30, 2014.
The company has registered 43.20% fall in its net profit at Rs 459.62 crore for the quarter under review as compared to Rs 809.12 crore for the same quarter in the previous year. Total income of the company has decreased 7.62% at Rs 2347.83 crore for Q2FY15 as compared Rs 2541.48 crore for the corresponding quarter previous year.
On consolidated basis, the company’s net profit after taxes and minority interest for the quarter under review registered 55.11% growth at Rs 630.04 crore against Rs 406.18 crore in the September quarter of previous fiscal. The company’s total income has increased by 19.44% at Rs 3283.64 crore for the quarter from Rs 2749.23 crore in the similar quarter of previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.00 |
| Dr. Reddys Lab | 1287.55 |
| Cipla | 1309.80 |
| Zydus Lifesciences | 953.80 |
| Lupin | 2270.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: